Enanta Pharmaceuticals, Inc. (ENTA)

NASDAQ: ENTA · IEX Real-Time Price · USD
56.49 -0.60 (-1.05%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap1.15B
Revenue (ttm)97.07M
Net Income (ttm)-79.00M
Shares Out20.32M
EPS (ttm)-3.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume222,750
Open56.49
Previous Close57.09
Day's Range56.44 - 58.70
52-Week Range40.37 - 102.00
Beta0.53
AnalystsBuy
Price Target89.50 (+58.4%)
Earnings DateFeb 8, 2022

About ENTA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepat...

IndustryBiotechnology
IPO DateMar 21, 2013
CEOJay Luly
Employees155
Stock ExchangeNASDAQ
Ticker SymbolENTA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ENTA stock is "Buy." The 12-month stock price forecast is 89.50, which is an increase of 58.44% from the latest price.

Price Target
$89.50
(58.44% upside)
Analyst Consensus: Buy

News

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2022 at the 40th A...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Provide Updates on its R&D Programs and Outlook for 2022 at the 40th Annual J.P. Morgan Healthcare Conference

2 weeks ago - Business Wire

Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

2 weeks ago - Business Wire

7 A-Rated Biotechs to Buy for the Long Run

The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.

1 month ago - InvestorPlace

Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 6.87% and 33.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021

2 months ago - Business Wire

Is a Surprise Coming for Enanta Pharmaceuticals (ENTA) This Earnings Season?

Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

Enanta Pharmaceuticals to Participate in December Investor Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Participate in December Investor Conferences

2 months ago - Business Wire

Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus Program

2 months ago - Business Wire

Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Enanta Pharmaceuticals to Host Conference Call on November 22 at 4:30 p.m. ET to Discuss its Financial Results for it...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta to Host Conference Call on November 22 to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021

2 months ago - Business Wire

Enanta Pharmaceuticals Reports Positive Final Data from its Phase 1b Studies of EDP-514, a Novel Hepatitis B Virus Co...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Positive Final Data from its Phase 1b Studies of EDP-514, a Novel Hepatitis B Virus Core Inhibitor.

2 months ago - Business Wire

3 Explosive Biotech Stocks -- Could They Shoot Even Higher?

These biotech stocks have recently been responsible for a slew of rocketship emojis.

Other symbols:CARAOCGN
2 months ago - The Motley Fool

4 Small Drug Stocks That Hold Promise Despite Industry Challenges

Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry players' third-quarter results. XNCR, ENTA, CPRX and MTEM may prove to be good additions to one's portfolio.

Other symbols:CPRXMTEMXNCR
2 months ago - Zacks Investment Research

Enanta Plans To Start Human Trials For Its COVID-19 Candidate In 2022

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has reported new preclinical data for EDP-235, its recently announced lead oral protease inhibitor for COVID-19.  The data were presented at the International S...

3 months ago - Benzinga

Enanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference

3 months ago - Business Wire

Enanta Pharmaceuticals (ENTA) Moves 10.6% Higher: Will This Strength Last?

Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mor...

3 months ago - Zacks Investment Research

New Preclinical Data for EDP-235, Enanta's Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-1...

WATERTOWN, Mass.--(BUSINESS WIRE)--New Preclinical Data for EDP-235, Enanta's Oral Protease Inhibitor for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference

3 months ago - Business Wire

Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference

3 months ago - Business Wire

Enanta To Discontinue Internal Development Of NASH Candidates

After looking at interim phase 2b data, Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has decided to stop the monotherapy trial of EDP-305 for non-alcoholic steatohepatitis (NASH). Instead, Enanta now plans...

3 months ago - Benzinga

Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs

3 months ago - Business Wire

Enanta Pharmaceuticals Announces Data Presentations at AASLD's The Liver Meeting® 2021

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Data Presentations at AASLD's The Liver Meeting® 2021

3 months ago - Business Wire

Enanta Pharmaceuticals to Participate in Investor Conferences in September

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Participate in Two Investor Conferences in September

4 months ago - Business Wire

Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors

5 months ago - Business Wire

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Des...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, its Oral Hepatitis B Virus RNA Destabilizer

5 months ago - Business Wire

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Misses Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 15.60% and -1.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research